UBS Maintains a “Buy” on Merck, Despite Potential Nasonex Generic Competition (MRK)

By
A A A
Share |

Drug maker Merck & Co., Inc. ( MRK ) on Monday received some continued bullish support from analysts at UBS.

The firm maintained its "Buy" rating and $42 price target on UBS, which suggests an 8% upside to the stock's Friday closing price of $38.94.

A UBS analyst noted he is not concerned right now about potential generic competition for the company's Nasonex drug. On Friday, a New Jersey judge ruled that generic competitor Apotex does not infringe on Merck's patent for mometasone furoate monohydrate.

Merck shares were mostly flat in late morning trading Monday.

The Bottom Line
Shares of Merck ( MRK ) have a 4.31% dividend yield, based on Friday's closing stock price of $38.94. The stock has technical support in the $36 price area. If the shares can firm up, we see overhead resistance around the $39-$40 price levels.

Merck & Co., Inc. ( MRK ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Created by Dividend.com


This article appears in: Investing , Stocks

Referenced Stocks: MRK

Dividend.com

Dividend.com

More from Dividend.com:

Related Videos

Stocks

Referenced

89%

Most Active by Volume

56,754,363
  • $74.36 ▼ 1.98%
51,749,769
  • $9.34 ▼ 6.60%
30,426,859
  • $16.995 ▲ 0.03%
28,852,903
  • $41.90 ▼ 0.43%
26,223,584
  • $32.815 ▼ 3.26%
25,135,587
  • $11.42 ▲ 1.87%
23,762,711
  • $4.55 ▼ 15.43%
21,683,661
  • $5.99 ▼ 0.17%
As of 10/30/2014, 12:49 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com